This newslink doesn't exist or it was removed.
Go to Homempage.
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
MarketWatch USA Business January 31, 2024
The Aduhelm commercial program had been all but dead since 2022, when the Centers for Medicare & Medicaid Services (CMS) declined to offer Medicare coverage for the drug. Biogen had been continuing of Aduhelm, however, as a condition of the Food and Drug Administration’s... + más
Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
The Boston Globe USA Business July 25, 2023
Biogen said Tuesday that it plans to cut about 1,000 jobs, roughly 11 percent of its global workforce, to lower costs as the Cambridge-based biotech begins to roll out the new Alzheimer’s drug it co-developed and prepares for possible approval of another drug, for depression,... + más
FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says | Fox Business
WPLG Local 10 USA Health January 31, 2024
Biogen will stop developing its Alzheimer’s treatment , a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug... + más
About iurex | Privacy Policy | Disclaimer |